Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 408.18 USD 0.72% Market Closed
Market Cap: 105.1B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

Gross Margin
Vertex Pharmaceuticals Inc

86.1%
Current
88%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
86.1%
=
Gross Profit
9.2B
/
Revenue
10.6B

Gross Margin Across Competitors

Country US
Market Cap 105.2B USD
Gross Margin
86%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 318.1B USD
Gross Margin
67%
Country US
Market Cap 142.2B USD
Gross Margin
60%
Country US
Market Cap 117.1B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36.2B EUR
Gross Margin
89%
Country US
Market Cap 31.3B USD
Gross Margin
85%
No Stocks Found

Vertex Pharmaceuticals Inc
Glance View

Market Cap
105.2B USD
Industry
Biotechnology
Economic Moat
Narrow

In the bustling landscape of biotechnology, Vertex Pharmaceuticals Inc. stands out as a dynamic powerhouse that has deftly carved a niche in the complex domain of genetic therapies. Founded in 1989, the company initially embarked on a mission to revolutionize drug discovery through a cutting-edge rational drug design approach. Armed with an innovative spirit and a focus on niche markets, Vertex turned its attention towards cystic fibrosis—a life-shortening genetic disorder affecting the lungs and digestive system. The company’s breakthrough came with the development and approval of the first therapies that address the underlying cause of cystic fibrosis, rather than just alleviating symptoms. These products, including Kalydeco and Trikafta, have repositioned Vertex from a scrappy biotech upstart to a dominating force in the drug market as these life-changing treatments not only improve patient outcomes but also command premium pricing. Vertex’s business model brilliantly capitalizes on its deep investment in research and development, allowing it to maintain a robust pipeline that promises ongoing growth. By channeling a substantial portion of its revenue back into R&D, Vertex seeks to extend its therapeutic successes beyond cystic fibrosis into other serious diseases with high unmet needs, such as sickle cell disease and beta-thalassemia. This strategic reinvestment supports a cyclical framework of innovation—capitalize on current successes while laying down the groundwork for future therapies. With a singular focus on specialty drugs that target specific genetic mutations or pathways, Vertex not only thrives on the immediate financial returns of its blockbuster drugs but continually invests in scientifically ambitious endeavors, thus reinforcing its status as a leader in the precision medicine sector.

VRTX Intrinsic Value
260.53 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
86.1%
=
Gross Profit
9.2B
/
Revenue
10.6B
What is the Gross Margin of Vertex Pharmaceuticals Inc?

Based on Vertex Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 86.1%.